Ivan Kairatov has spent decades at the center of biopharmaceutical innovation, specializing in the high-stakes world of respiratory research and development. His expertise in dissecting the clinical and strategic failures of major drug candidates has made him a leading voice for investors and scientists trying to navigate the volatile landscape of late-stage drug trials. Today, we sit down with him to discuss the recent decision by GSK to shelf camlipixant, a chronic cough treatment once valued at $2 billion. This conversation explores the biological complexity of the P2X3 antagonist class, the ripple effects on the competitive market, and how pharmaceutical giants like GSK are pivoting their portfolios toward oncology to mitigate the risks of clinical setbacks.
The P2X3 antagonist class was once heralded as a revolutionary approach to treating chronic cough, yet we have seen heavyweights like Bayer, Merck, and now GSK struggle to reach the finish line. From an R&D perspective, why has this specific pathway proven so difficult to master?
The P2X3 receptor pathway seemed like a biological certainty on paper because it directly targets the sensory nerves responsible for the cough reflex, but the reality of clinical translation has been bruising for the entire industry. We are seeing a recurring pattern where these drugs fail to demonstrate a treatment effect that significantly outweighs the placebo, often due to the subjective nature of cough reporting and the high variability in patient populations. When you look at Merck’s $500 million investment and Bayer’s similar setbacks, it suggests a fundamental challenge in finding a dose that is potent enough to stop the cough without causing significant side effects or being lost in the clinical “noise.” GSK’s decision to pull the plug after their massive $2 billion acquisition of Bellus Health really underscores that even with sophisticated R&D resources, this specific mechanism remains an incredibly difficult target to hit.
When we examine the Phase 3 results for camlipixant, the data seems particularly inconsistent, with the 50-milligram dose showing promise in one trial but failing in another. How does a clinical team interpret such conflicting signals during late-stage development?
It is a devastating scenario for a development team when you see a statistically significant reduction in 24-hour cough frequency at the 50-milligram dose in one experiment, only for it to completely fall flat in the second. In this specific case, the lower 25-milligram dose failed across the board, and the fact that both studies missed their key secondary goals signaled that the drug was never going to be the transformative care GSK promised. This kind of “limited efficacy” is a death knell in modern pharma because regulators are looking for robust, undeniable outcomes, not marginal improvements that might disappear in a broader real-world setting. The team had to make the cold, hard calculation that the data simply did not support a multibillion-dollar blockbuster launch, leading to the decision to cease development for this indication.
Despite the failure in respiratory medicine, GSK mentioned they are continuing Phase 2 trials for irritable bowel syndrome. Is this a common strategy to salvage value from a multi-billion dollar asset, or is there a genuine biological rationale for this pivot?
Pivoting to another indication like irritable bowel syndrome is a calculated move to protect the initial $2 billion investment, and it is backed by the biological fact that P2X3 receptors are also prevalent in the gastrointestinal tract. While camlipixant failed to provide the necessary relief for chronic cough, the sensory signaling pathways in the gut might respond differently to the same chemical mechanism. However, the bar for success in the GI space is arguably just as high, and the company will need to see much more consistent data than the “mixed” results we witnessed in the cough trials. It represents a necessary “Plan B” that keeps the asset alive on the balance sheet, even though the massive commercial opportunity originally envisioned for the respiratory market has evaporated.
The market reacted quite strongly to this news, particularly regarding smaller competitors. How do you see the competitive landscape shifting now that several major P2X3 candidates have been sidelined by the industry leaders?
What is a massive loss for GSK has become an “open field opportunity” for companies like Trevi Therapeutics, whose shares rose as much as 16% in morning trading immediately following the announcement. Trevi is taking a fundamentally different approach with Haduvio, an opioid they have repurposed from pain relief for use in chronic cough and idiopathic pulmonary fibrosis. By moving away from the P2X3 mechanism that has now claimed three major victims, they are positioning themselves as the primary alternative for patients who have exhausted all other options. If their upcoming trials can demonstrate the consistency that GSK and Merck missed, they will find themselves in an enviable market position with almost no direct competition left in the late-stage pipeline.
Analysts have noted that this failure doesn’t necessarily damage the long-term GSK story because of a shift toward oncology. How does a company balance these high-profile R&D losses while trying to convince investors of a new strategic direction?
It is a delicate balancing act for leadership, especially since the current CEO and R&D chief were deeply involved in the Bellus acquisition and cannot be entirely absolved from the failure. However, the investment narrative is increasingly centered on GSK’s oncology portfolio, where recent acquisitions and internal assets offer substantially larger and longer-duration value creation opportunities. Investors tend to be more forgiving of R&D failures if they see a robust pipeline in high-growth areas like cancer treatment, and GSK is betting that their shift away from respiratory staples will pay off. The termination of camlipixant is disappointing, but in the grand scheme of a multi-billion dollar pharma strategy, it is seen as a necessary pruning to focus resources where the chances of success are higher.
What is your forecast for the chronic cough treatment market over the next five years?
I expect a period of intense recalibration where we see a definitive move away from the P2X3 antagonist class in favor of more diverse mechanisms, including neuromodulators and repurposed compounds. The high-profile exits of GSK, Merck, and Bayer have left a massive vacuum in a market with millions of underserved patients, which will likely trigger a new wave of smaller, agile biotech firms entering the space with novel targets. While the “blockbuster” dream for P2X3 might be fading, the clinical need is still growing, and the next success story will likely come from a company that can solve the placebo-effect riddle that has haunted this therapeutic area for the last decade.
